top of page

Fluidx is redefining embolization with an easy-to-use and highly controllable ionic gel embolization platform, which will be used to treat a wide range of conditions including tumors, hemorrhage, and targeted neurovascular bleeds. 

Syringe_edited.png

Consistent. Fast. Complete. 

Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device

The final module of the submission included results from the pivotal IDE trial that enrolled 114 patients at 18 sites in the United States, Canada, and New Zealand.

Embolic Technologies

GPX Image.png
GPX Embolic Device Horiz.png

Peripheral distal embolic

ULTRA logo Horizontal tm.png

Peripheral embolics for hemorrhage and other applications

Impass Image.jpg
IMPASS logo horizontal tm.png

Neurovascular distal embolic

Latest Press

GPX Embolic Device syringe
Fluidx Medical Closes Financing to Advance Next-Generation Embolic Platforms
7 August 2026
Learn More
Image of the GPX Embolic Device, a novel liquid embolic.
Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device
24 July 2026
Learn More
Image of a syringe containing the novel, easy to use, GPX embolic material
GPX® Embolic Device meets Primary Endpoints in an Investigational Device
Exemption (IDE) Pivotal Trial
14 July 2026
Learn More
The visible, controllable ULTRA gel embolic is delivered to a large renal tumor.
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
3 July 2026
Learn More
info@fluidxmedical.com

Fluidx Medical’s GPX Embolic Device – durable liquid embolic

* Data on file. Fluidx Medical Technology, Inc.

The GPX Embolic Device, ULTRA Embolic Platform, and IMPASS Embolic Device are under development and do not have marketing clearance or approval in any market at this time. 

bottom of page